Drug Trial Radar · NCT04061421
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
Nov 24, 2021
Primary completion
Aug 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Michael SavonaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Incyte Corporation; Theradex; Astex Pharmaceuticals, Inc.
- First posted
- Aug 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will test an active myeloid target compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in a single tablet.
Conditions
- MDS/MPN
Interventions
ASTX727Drug
Taken by mouth daily during days 1-5 of every 28-day cycle.
ItacitinibDrug
Taken by mouth daily during each 28-day cycle
RuxolitinibDrug
Dosage will be 5,15, or 20mg Taken by mouth BID for 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Determination of doseTime frame: Up to 28 days
- Phase 2: Overall response rate (ORR). Overall response includes patients who achieve best response of CR, PR, MR, or CB as defined by the MDS/MPN IWG proposed response criteriaTime frame: Up to 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Moffitt Cancer Center
Tampa, Florida · Recruiting
University of Rochester Wilmot Cancer Institute
Rochester, New York · Recruiting
Oregon Health Sciences University
Portland, Oregon · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.